Treg engineers take aim at autoimmunity
Elie Dolgin • November 9, 2021
Companies are deploying regulatory T cells, equipped with CAR and TCR constructs, to suppress immunity — locally and for the long term.
Engineered adoptive T-cell therapies have already transformed the treatment of blood cancers. Now, several startups hope to harness the power of regulatory T cells (Tregs) to suppress immune responses and offer tolerance to transplant recipients, or to control the inflammation driving autoimmune disorders.
Continue reading at Nature Biotechnology.
Zebras and giraffes offer one another protection without food competition.
Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with fewer side effects.